Vishnudat Seodat, MD
Family Medicine · Riverhead, NYNPI 1205919115
Payments from drug & device makers
Across 189 payments — averaging $30.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$629
- Boehringer Ingelheim$553
- Novo Nordisk$544
- AbbVie$498
- GSK$494
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,67698%
- Education$1222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $1,095 |
| Amgen | 12 | $629 |
| Boehringer Ingelheim | 14 | $553 |
| Novo Nordisk | 38 | $544 |
| AbbVie(2 entities) | 9 | $498 |
| GSK | 15 | $494 |
| Bayer | 16 | $466 |
| Amarin Pharma, Inc. | 6 | $223 |
| Novartis | 9 | $195 |
| Lilly USA, LLC | 7 | $171 |
| Idorsia Pharmaceuticals US Inc | 6 | $142 |
| Esperion Therapeutics, Inc. | 3 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $127 |
| Johnson & Johnson | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 5 | $110 |
| Arbor Pharmaceuticals, Inc. | 2 | $43 |
| Exact Sciences | 2 | $42 |
| Abbott | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Pfizer | 1 | $25 |
| Philips North America LLC | 1 | $24 |
| Medtronic | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,798 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 201 | $243,679 |
| MounjaroTirzepatide | 187 | $231,270 |
| EliquisApixaban | 174 | $216,161 |
| JardianceEmpagliflozin | 163 | $214,278 |
| OzempicSemaglutide | 163 | $213,667 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 154 | $151,237 |
| Repatha SureclickEvolocumab | 94 | $88,495 |
| KerendiaFinerenone | 58 | $63,556 |
| XareltoRivaroxaban | 43 | $54,893 |
| WegovySemaglutide | 26 | $40,777 |
| RybelsusSemaglutide | 14 | $31,890 |
| EntrestoSacubitril/Valsartan | 30 | $30,570 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $30,502 |
| Repatha SyringeEvolocumab | 28 | $26,988 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $26,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus | $544 | $286,334203 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,095 | $274,181242 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $553 | $247,012191 claims |
| Lilly USA, LLCMounjaro | $171 | $231,270187 claims |
| PfizerEliquis | $25 | $216,161174 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $494 | $179,529193 claims |
| BayerKerendia | $466 | $63,55658 claims |
| Johnson & JohnsonXarelto | $125 | $54,89343 claims |
| AbbVieLinzess, Synthroid | $498 | $31,187154 claims |
| NovartisEntresto | $195 | $30,57030 claims |
| AmgenProlia | $629 | $21,82613 claims |
| Esperion Therapeutics, Inc.Nexlizet | $140 | $20,86624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Riverhead
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.